Cargando…

Evaluation of malignant effusions using MR-based T1 mapping

Our aim was to investigate the diagnostic yield of rapid T1-mapping for the differentiation of malignant and non-malignant effusions in an ex-vivo set up. T1-mapping was performed with a fast modified Look-Locker inversion-recovery (MOLLI) acquisition and a combined turbo spin-echo and inversion-rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuetting, D., Luetkens, J., Faron, A., Isaak, A., Attenberger, U., Pieper, C. C., Meffert, L., Jansen, C., Sprinkart, A., Kütting, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007641/
https://www.ncbi.nlm.nih.gov/pubmed/33782528
http://dx.doi.org/10.1038/s41598-021-86632-1
_version_ 1783672534318710784
author Kuetting, D.
Luetkens, J.
Faron, A.
Isaak, A.
Attenberger, U.
Pieper, C. C.
Meffert, L.
Jansen, C.
Sprinkart, A.
Kütting, F.
author_facet Kuetting, D.
Luetkens, J.
Faron, A.
Isaak, A.
Attenberger, U.
Pieper, C. C.
Meffert, L.
Jansen, C.
Sprinkart, A.
Kütting, F.
author_sort Kuetting, D.
collection PubMed
description Our aim was to investigate the diagnostic yield of rapid T1-mapping for the differentiation of malignant and non-malignant effusions in an ex-vivo set up. T1-mapping was performed with a fast modified Look-Locker inversion-recovery (MOLLI) acquisition and a combined turbo spin-echo and inversion-recovery sequence (TMIX) as reference. A total of 13 titrated albumin-solutions as well as 48 samples (29 ascites/pleural effusions from patients with malignancy; 19 from patients without malignancy) were examined. Samples were classified as malignant-positive histology, malignant-negative histology and non-malignant negative histology. In phantom analysis both mapping techniques correlated with albumin-content (MOLLI: r = − 0.97, TMIX: r = − 0.98). MOLLI T1 relaxation times were shorter in malignancy-positive histology fluids (2237 ± 137 ms) than in malignancy-negative histology fluids (2423 ± 357 ms) as well as than in non-malignant-negative histology fluids (2651 ± 139 ms); post hoc test for all intergroup comparisons: < 0.05. ROC analysis for differentiation between malignant and non-malignant effusions (malignant positive histology vs. all other) showed an (AUC) of 0.89 (95% CI 0.77–0.96). T1 mapping allows for non-invasive differentiation of malignant and non-malignant effusions in an ex-vivo set up.
format Online
Article
Text
id pubmed-8007641
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80076412021-03-30 Evaluation of malignant effusions using MR-based T1 mapping Kuetting, D. Luetkens, J. Faron, A. Isaak, A. Attenberger, U. Pieper, C. C. Meffert, L. Jansen, C. Sprinkart, A. Kütting, F. Sci Rep Article Our aim was to investigate the diagnostic yield of rapid T1-mapping for the differentiation of malignant and non-malignant effusions in an ex-vivo set up. T1-mapping was performed with a fast modified Look-Locker inversion-recovery (MOLLI) acquisition and a combined turbo spin-echo and inversion-recovery sequence (TMIX) as reference. A total of 13 titrated albumin-solutions as well as 48 samples (29 ascites/pleural effusions from patients with malignancy; 19 from patients without malignancy) were examined. Samples were classified as malignant-positive histology, malignant-negative histology and non-malignant negative histology. In phantom analysis both mapping techniques correlated with albumin-content (MOLLI: r = − 0.97, TMIX: r = − 0.98). MOLLI T1 relaxation times were shorter in malignancy-positive histology fluids (2237 ± 137 ms) than in malignancy-negative histology fluids (2423 ± 357 ms) as well as than in non-malignant-negative histology fluids (2651 ± 139 ms); post hoc test for all intergroup comparisons: < 0.05. ROC analysis for differentiation between malignant and non-malignant effusions (malignant positive histology vs. all other) showed an (AUC) of 0.89 (95% CI 0.77–0.96). T1 mapping allows for non-invasive differentiation of malignant and non-malignant effusions in an ex-vivo set up. Nature Publishing Group UK 2021-03-29 /pmc/articles/PMC8007641/ /pubmed/33782528 http://dx.doi.org/10.1038/s41598-021-86632-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kuetting, D.
Luetkens, J.
Faron, A.
Isaak, A.
Attenberger, U.
Pieper, C. C.
Meffert, L.
Jansen, C.
Sprinkart, A.
Kütting, F.
Evaluation of malignant effusions using MR-based T1 mapping
title Evaluation of malignant effusions using MR-based T1 mapping
title_full Evaluation of malignant effusions using MR-based T1 mapping
title_fullStr Evaluation of malignant effusions using MR-based T1 mapping
title_full_unstemmed Evaluation of malignant effusions using MR-based T1 mapping
title_short Evaluation of malignant effusions using MR-based T1 mapping
title_sort evaluation of malignant effusions using mr-based t1 mapping
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007641/
https://www.ncbi.nlm.nih.gov/pubmed/33782528
http://dx.doi.org/10.1038/s41598-021-86632-1
work_keys_str_mv AT kuettingd evaluationofmalignanteffusionsusingmrbasedt1mapping
AT luetkensj evaluationofmalignanteffusionsusingmrbasedt1mapping
AT farona evaluationofmalignanteffusionsusingmrbasedt1mapping
AT isaaka evaluationofmalignanteffusionsusingmrbasedt1mapping
AT attenbergeru evaluationofmalignanteffusionsusingmrbasedt1mapping
AT piepercc evaluationofmalignanteffusionsusingmrbasedt1mapping
AT meffertl evaluationofmalignanteffusionsusingmrbasedt1mapping
AT jansenc evaluationofmalignanteffusionsusingmrbasedt1mapping
AT sprinkarta evaluationofmalignanteffusionsusingmrbasedt1mapping
AT kuttingf evaluationofmalignanteffusionsusingmrbasedt1mapping